First clinical evidence shows oxidized cholesterol driving atherosclerosis can be safely removed

Cyclarity Therapeutics has released safety data from a phase 1 clinical trial demonstrating that 7-ketocholesterol (7KC), a root cause of atherosclerosis, can be safely targeted and removed from the human body for the first time. UDP-003, the lead candidate engineered using Cyclarity's proprietary AI-driven cyclodextrin platform, binds directly to 7KC and facilitates its urinary excretion, circumventing the systemic effects inherent to conventional cardiovascular drugs like statins and anti-inflammatories. Rather than modulating cholesterol metabolism system-wide, this localized mechanism addresses a primary driver of plaque toxicity and instability within the arterial environment itself. The company is actively enrolling acute coronary syndrome patients into the efficacy cohort, with pre- and post-treatment coronary CT angiography to quantify plaque changes. Beyond cardiovascular disease, 7KC has emerged as a pathogenic factor in Alzheimer's disease, metabolic dysfunction-associated steatohepatitis, and age-related conditions broadly, positioning this technology as a potential paradigm shift in regenerative arterial medicine for the longevity-conscious clinician and biohacker.